Novartis Drug Failure in Rare Vascular Disorder Trial

Novartis’s Cosentyx antibody drug failed to outperform placebo in a pivotal Phase 3 clinical study targeting giant cell arteritis, a rare autoimmune blood vessel disease. The failure impedes Novartis’s efforts to expand Cosentyx’s indications, where competitors Roche and AbbVie already hold approved therapies. This setback signals challenges in novel treatment development for rare vascular inflammatory disorders.